Articles published by ImmunityBio, Inc.

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

August 10, 2026

Tickers IBRX

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 04, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

July 29, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

June 01, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

May 18, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

May 16, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

May 07, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

May 05, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

April 21, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

April 09, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

April 06, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

March 31, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

March 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

February 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

February 19, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

February 18, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

February 17, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

Tickers IBRX

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.